Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 389,886 shares of the biopharmaceutical company’s stock after selling 8,980 shares during the quarter. Victory Capital Management Inc. owned about 0.60% of Regulus Therapeutics worth $616,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. NEA Management Company LLC bought a new stake in shares of Regulus Therapeutics during the 3rd quarter worth about $10,154,000. State Street Corp raised its position in shares of Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 33,496 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Regulus Therapeutics during the 3rd quarter worth about $1,403,000. The Manufacturers Life Insurance Company bought a new stake in shares of Regulus Therapeutics during the 3rd quarter worth about $204,000. Finally, Barclays PLC raised its position in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 62,549 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Stock Up 0.7 %

RGLS stock opened at $1.37 on Friday. The firm has a 50 day moving average of $1.27 and a two-hundred day moving average of $1.45. Regulus Therapeutics Inc. has a 12 month low of $0.83 and a 12 month high of $3.00. The company has a market capitalization of $90.75 million, a price-to-earnings ratio of -1.28 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). During the same quarter last year, the firm earned ($0.40) earnings per share. On average, research analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analyst Ratings Changes

RGLS has been the topic of a number of research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $28.00 target price on shares of Regulus Therapeutics in a report on Monday, March 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Friday, March 14th.

Insider Activity at Regulus Therapeutics

In other Regulus Therapeutics news, CFO Crispina Calsada sold 38,716 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,782.16. Following the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at $63,713.16. This represents a 43.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph P. Hagan sold 115,290 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $145,265.40. Following the sale, the chief executive officer now directly owns 222,572 shares in the company, valued at approximately $280,440.72. This represents a 34.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 in the last ninety days. 4.35% of the stock is currently owned by insiders.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.